Advancing Pharmacovigilance Talent for AI: Overcoming Skills and Resource Barriers
John Praveen, Associate Vice President, Accenture
In the evolving world of pharmacovigilance, artificial intelligence revolutionises drug safety by automating data processing, enhancing signal detection, and enabling real-time risk prediction. Success demands workforce reskilling in AI literacy, advanced analytics, and ethical oversight. Organisations must invest in comprehensive training and adaptive strategies to empower people and optimise resources, ensuring effective, compliant, and future-ready pharmacovigilance systems that elevate patient safety globally.
Introduction:
In the transforming field of pharmacovigilance (PV), artificial intelligence (AI) is reshaping how drug safety is monitored and managed. As PV evolves from manual, reactive workflows to sophisticated AI-augmented systems, the imperative for comprehensive workforce upskilling grows stronger. Organisations and professionals must adapt to new technical demands, regulatory requirements, and ethical challenges to ensure optimal outcomes. This article explores the multidimensional upskilling needed for this transformation, highlighting the importance of digital and data literacy—including managing AI biases and hallucinations—alongside analytical prowess, regulatory understanding, and soft skills development.
The Changing Pharmacovigilance Landscape: A Call for Upskilling
The pharmacovigilance domain is rapidly evolving due to the growing volumes and varieties of data sources such as electronic health records, social media, and real-world evidence. Traditional manual methods of case processing and signal detection struggle to keep pace with this complexity. AI-powered tools utilising machine learning (ML), natural language processing (NLP), Large Language Models (LLM) and advanced analytics deliver near real-time insights that improve safety surveillance and risk predictions.
However, the introduction of AI is more than a simple technological upgrade; it demands a fundamental shift in workforce capabilities. Professionals must not only operate these systems but also interpret AI outputs, validate signals, and integrate findings with clinical knowledge and regulatory frameworks. The emerging PV model is a hybrid one—humans and AI working in close partnership to optimise patient safety.
Upskilling Needs: A Strategic and Multidimensional Challenge
1) Digital and Data Literacy with AI Transparency Focus
The cornerstone of effective AI integration in pharmacovigilance is a workforce well-versed in digital systems and data science principles. This knowledge base equips professionals to critically evaluate AI-generated outputs, reducing errors in safety signal detection and prediction.
Central to this is an understanding of AI transparency and explainability (Explainable AI or XAI). AI models, particularly complex ones based on ML, can produce outputs that are not always intuitive or fully understood without interpretive tools. Moreover, AI systems can exhibit two critical issues:
- AI hallucinations: These are instances where AI algorithms generate inaccurate, fabricated, or nonsensical outputs that do not correspond to the underlying data or reality. In pharmacovigilance, hallucinations can cause false safety signals or overlook important risks.
- AI biases: Bias emerges from training data that is unrepresentative, incomplete, or skewed, or from algorithmic design choices, leading to systemic errors that disproportionately affect certain patient groups or safety outcomes.
Pharmacovigilance professionals must learn how AI models are trained, validated, and deployed, including data preprocessing and quality control measures that reduce these risks. They also need to develop skills to detect AI hallucinations and biases proactively and critically assess AI outputs before acting on them. This ensures AI-aided decisions are transparent, auditable, and align with regulatory demands for safety and ethics.
2) Advanced Analytical and Interdisciplinary Skills
Interpreting AI-derived data and signals requires hybrid capabilities combining deep domain knowledge with advanced analytical and data interpretation skills. PV professionals should be equipped to critically appraise AI-driven findings and collaborate closely with data scientists, IT teams, clinicians, and regulatory experts. Strong communication, adaptability, and systems thinking foster effective teamwork and ensure AI tools are used to their fullest potential.
3) Regulatory and Ethical Acumen
Global regulatory bodies such as the FDA, EMA, and WHO are increasingly issuing guidance specific to AI applications in pharmacovigilance. PV professionals must stay current with these evolving regulations, which emphasise risk-based AI validation frameworks and ethical considerations around data privacy, patient safety, and AI accountability. Ethical governance plays a vital role in aligning AI-enabled PV operations with societal expectations and legal mandates, preventing unintended consequences related to bias or errors.
What Individuals Must Do to Upskill
- Engage in Formal Training: Targeted certifications and courses on AI, digital pharmacovigilance, and data science help professionals build foundational and advanced knowledge. These programs often provide hands-on exposure to AI tools and regulatory context.
- Gain Practical Experience: Participation in AI implementation projects or cross-functional digital teams provides experiential learning, helping convert theoretical knowledge into actionable skills.
- Stay Updated on Regulatory Changes: Regularly monitoring global AI regulatory frameworks enables anticipation of compliance requirements and integration of best industry practices.
- Adopt a Growth Mindset: Lifelong learning, flexibility, and resilience prepare professionals for evolving careers in the AI-augmented pharmaceutical ecosystem.
What Organisations Must Do
- Design Comprehensive Reskilling Programs: Scalable, role-specific learning initiatives covering AI fundamentals, PV applications, regulatory compliance, and ethical governance are essential.
- Create a Culture of Learning: Encourage experimentation, knowledge-sharing, and cross-departmental collaboration to build trust in AI and augment human capabilities.
- Support Hands-On Learning: Provide access to AI sandbox environments, pilot projects, and masterclasses that enable practical AI skills development.
- Implement Ethical Governance: Develop frameworks for AI oversight, bias detection, risk management, and data privacy aligned with regulatory expectations, ensuring responsible AI deployment.
- Lead Transparent Change Management: Communicate clearly about AI integration benefits, mitigate employee fears about job shifts, and clarify new career pathways.
Staying Relevant: Balancing Human Expertise and AI Capabilities
In the fast-evolving AI-augmented PV environment, relevance depends on harmonising human insight with machine intelligence. Key strategies include:
- Human-AI Partnership Mindset: View AI as an augmentation tool requiring human validation for complex risk judgments and ethical evaluations.
- Continuous Skill Assessment: Regularly evaluate and close skill gaps related to emerging AI technologies and methodologies.
- Cross-Functional Collaboration: Expand integration with clinical development, regulatory science, and quality assurance to reflect the interconnected pharma landscape.
- Leverage AI-Driven Learning Platforms: Use adaptive, personalised digital training to accelerate skill acquisition and retention.
- Build Thought Leadership: Engage in industry forums and publications to share best practices and shape AI’s safe, ethical adoption.
Conclusion
Pharmacovigilance professionals and organisations stand at a pivotal crossroads in the era of AI-assisted drug safety monitoring. Success requires comprehensive upskilling, combining digital literacy, especially around AI transparency and bias detection, with analytical capability, regulatory understanding, and interpersonal skills.
Individuals proactive about continuous education, interdisciplinary cooperation, and adaptability will thrive amidst ongoing change. Organisations fostering strategic upskilling, nurturing innovative cultures, and committing to ethical AI governance will enhance patient safety and secure competitive advantage.
The future of pharmacovigilance lies not in humans versus machines but in a synergistic partnership that leverages the unique strengths of both. Lifelong learning, agility, and judgment remain central to safeguarding patients in this data-rich, AI-enhanced pharmaceutical era.
John Praveen is an accomplished Pharmacovigilance (PV) and Medical Writing (MW) professional with over 15+ years of experience in Product Safety (across Pharmacovigilance, Medical Device Vigilance, Hemovigilance, and Cosmetovigilance). As Associate Vice President at Accenture, he oversees PV/MW Portfolio Delivery, Shared Services, and Managed Services. John's academic background includes bachelor's and master’s degrees in Biological Science, Microbiology & Immunology, and a PG Diploma in Medical Entomology and Medical Genetics from St. Joseph's University, Bangalore. He also holds a management degree from the Indian Institute of Management, Lucknow, and is certified by Accenture.
